Even if RNA-based therapeutics have been under development for over 30 years, it was the COVID-19 pandemic that brought them into the limelight, with the rapid development of mRNA-based vaccines against the SARS-Cov2 virus by Moderna and BioNTech/Pfizer. And lipid Nanoparticles (LNPs), used to efficiently deliver mRNA, are key players of this technology.

Many researchers are facing the challenges of mRNA delivery, through the body into the cytoplasm of cells. In this post, we invite you to discover some useful and efficient solutions to improve and control all the steps of your mRNA delivery project.

Every type of cell has different membrane properties, meaning that transfection of your specific nucleic acid can become challenging.

To overcome transfection limitations, RJH Biosciences have developed a new range of transfection reagents to transfect mammalian cells with specific nucleic acids.

Access to this new technology now through tebu-bio in Europe!  

This summer, Moffett et al. published in Nature Communications (Nature Communications – doi:10.1038/s41467-017-00505-8) a new approach for cancer therapeutic research and development based on mRNA delivery. They called it ‘Hit-and-run programming’ because of the simplicity of the method. Interestingly, the optimization of the delivery was performed with eGFP mRNA.  This post describes how TriLink’s mRNAs contribute to the simple and efficient delivery of mRNA into cells.